Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

SQI Diagnostics Inc V.SQD.H

SQI Diagnostics Inc. is a Canada-based company that is focused on lung health. The Company is engaged in the development and manufacturing of respiratory health and precision medicine tests that run on its fully automated systems. Its clinical solutions include Rapid Acute Lung Injury Diagnostic (RALI-Dx), lung transplant diagnostics, COVID-19 testing and surveillance testing solutions. Its RALI-Dx IL-6 Severity Triage Test and the RALI-fast IL-6 Severity Triage point of care (POC) Test each help clinicians identify which patients with SARS-CoV-2 are predicted to have a severe inflammatory response and should or should not be admitted to the hospital. Its RALI-Dx delivers results from the lab in less than an hour while RALI-fast delivers results at the patient point-of-care in about 15 minutes. The Company’s TORdx LUNG Test measures inflammation at the molecular level to assess the health of the donor lung. The Company is also focused on its organ transplant pipeline of products.


TSXV:SQD.H - Post by User

Post by FactFinder1994on Dec 06, 2020 11:02am
140 Views
Post# 32045903

RALI-fast TM COVID-19 POC Severity/Triage Test

RALI-fast TM COVID-19 POC Severity/Triage Test

Helps Predict Adverse Cytokine Event or Not

Measures IL-6 level, the most critical biomarker predictive of adverse respiratory event“cytokine storm”.

Rapid 15-minute result aides in diagnosing severity of COVID-19, influenza or other respiratory distressed patients.

Triage tool helps advise clinician to send patient home, admit to hospital and monitor or send to ICU for advanced respiratory care measures.

Saves lives, maximizes resources, reduces burden on healthcare system and prevents unnecessary hospital admissions and costs.

FDA has confirmed RALI-fastTM submission to be under Emergency Use Authorization (EUA).


<< Previous
Bullboard Posts
Next >>